Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.40 USD
-0.07 (-0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $17.40 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.40 USD
-0.07 (-0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $17.40 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth B Momentum C VGM
Zacks News
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.61% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Integra (IART) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Integra (IART) stock based on the movements in the options market lately.
Integra's (IART) New Site to Produce Recalled Tissue Products
by Zacks Equity Research
Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.
Why Is Integra (IART) Up 26% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is The Options Market Predicting A Spike In Integra LifeScience (IART) Stock?
by Zacks Equity Research
Investors need to pay close attention to Integra LifeScience (IART) stock based on the movements in the options market lately.
Deciphering Integra (IART) International Revenue Trends
by Zacks Equity Research
Examine the evolution of Integra's (IART) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Why Is Integra (IART) Down 4% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra LifeSciences (IART) Introduces MicroMatrix Flex
by Zacks Equity Research
Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
Integra's (IART) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.
Compared to Estimates, Integra (IART) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integra LifeSciences (IART) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -1.11% and 0.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Integra (IART), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Earnings Preview: Integra LifeSciences (IART) Q4 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Q4 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 2.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.53% and 1.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.